Abstract | INTRODUCTION: AREAS COVERED: In this article, authors describe the pharmacokinetic and pharmacodynamic properties of dabigatran etexilate and summarize the clinical evidence and controversy surrounding its use in the US, Canada and Europe. EXPERT OPINION:
|
Authors | Erika Hellenbart, Beatrice Drambarean, James Lee, Edith A Nutescu |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 16
Issue 13
Pg. 2053-72
( 2015)
ISSN: 1744-7666 [Electronic] England |
PMID | 26245513
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antithrombins
- Enoxaparin
- Pyrazoles
- Pyridines
- Pyridones
- Thiazoles
- apixaban
- Rivaroxaban
- Dabigatran
- edoxaban
|
Topics |
- Antithrombins
(pharmacokinetics, therapeutic use)
- Arthroplasty, Replacement, Knee
- Atrial Fibrillation
(drug therapy)
- Cardiovascular Diseases
(drug therapy)
- Clinical Trials as Topic
- Dabigatran
(pharmacokinetics, therapeutic use)
- Enoxaparin
(therapeutic use)
- Humans
- Pyrazoles
(therapeutic use)
- Pyridines
(therapeutic use)
- Pyridones
(therapeutic use)
- Rivaroxaban
(therapeutic use)
- Stroke
(prevention & control)
- Thiazoles
(therapeutic use)
- Venous Thromboembolism
(drug therapy)
|